» Articles » PMID: 33512602

Increased Susceptibility to Intensive Care Unit-acquired Pneumonia in Severe COVID-19 Patients: a Multicentre Retrospective Cohort Study

Abstract

Background: The aim of this study is to determine whether severe COVID-19 patients harbour a higher risk of ICU-acquired pneumonia.

Methods: This retrospective multicentre cohort study comprised all consecutive patients admitted to seven ICUs for severe COVID-19 pneumonia during the first COVID-19 surge in France. Inclusion criteria were laboratory-confirmed SARS-CoV-2 infection and requirement for invasive mechanical ventilation for 48 h or more. Control groups were two historical cohorts of mechanically ventilated patients admitted to the ICU for bacterial or non-SARS-CoV-2 viral pneumonia. The outcome of interest was the development of ICU-acquired pneumonia. The determinants of ICU-acquired pneumonia were investigated in a multivariate competing risk analysis.

Result: One hundred and seventy-six patients with severe SARS-CoV-2 pneumonia admitted to the ICU between March 1st and 30th June of 2020 were included into the study. Historical control groups comprised 435 patients with bacterial pneumonia and 48 ones with viral pneumonia. ICU-acquired pneumonia occurred in 52% of COVID-19 patients, whereas in 26% and 23% of patients with bacterial or viral pneumonia, respectively (p < 0.001). Times from initiation of mechanical ventilation to ICU-acquired pneumonia were similar across the three groups. In multivariate analysis, the risk of ICU-acquired pneumonia remained independently associated with underlying COVID-19 (SHR = 2.18; 95 CI 1.2-3.98, p = 0.011).

Conclusion: COVID-19 appears an independent risk factor of ICU-acquired pneumonia in mechanically ventilated patients with pneumonia. Whether this is driven by immunomodulatory properties by the SARS-CoV-2 or this is related to particular processes of care remains to be investigated.

Citing Articles

Risk factors for bloodstream infection in COVID-19 patients in intensive care units: a systematic review and meta-analysis.

Wang J, Jiang T BMC Infect Dis. 2025; 25(1):13.

PMID: 39754037 PMC: 11697680. DOI: 10.1186/s12879-024-10420-1.


Ventilator-Associated Pneumonia, Ventilator-Associated Events, and Nosocomial Respiratory Viral Infections on the Leeside of the Pandemic.

Klompas M Respir Care. 2024; 69(7):854-868.

PMID: 38806219 PMC: 11285502. DOI: 10.4187/respcare.11961.


Multidrug-resistant pathogens and ventilator-associated pneumonia in critically ill COVID-19 and non-COVID-19 patients: a prospective observational monocentric comparative study.

Montrucchio G, Balzani E, Sales G, Vaninetti A, Grillo F, Trompeo A Respir Res. 2024; 25(1):168.

PMID: 38637766 PMC: 11027225. DOI: 10.1186/s12931-024-02779-1.


The Impact of SARS-CoV-2 Infection on the Length of Stay in the Neuro-ICU:A Prospective Multicenter Cohort Study in Eight Neuro-ICU, China Between February and April 2023.

Tan L, Wang F, Huang Y, Fu C, Zhang H, Feng J Neuropsychiatr Dis Treat. 2024; 20:765-775.

PMID: 38577632 PMC: 10992672. DOI: 10.2147/NDT.S447887.


Quantity of antibiotic use and its association with clinical outcomes in COVID-19 patients: A snapshot from a provincial referral hospital in Indonesia.

Yossadania A, Hayati Z, Harapan H, Saputra I, Mudatsir , Diah M Narra J. 2024; 3(3):e272.

PMID: 38450336 PMC: 10914064. DOI: 10.52225/narra.v3i3.272.


References
1.
Hotchkiss R, Monneret G, Payen D . Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis. 2013; 13(3):260-8. PMC: 3798159. DOI: 10.1016/S1473-3099(13)70001-X. View

2.
Melsen W, Rovers M, Groenwold R, Bergmans D, Camus C, Bauer T . Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis. 2013; 13(8):665-71. DOI: 10.1016/S1473-3099(13)70081-1. View

3.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054-1062. PMC: 7270627. DOI: 10.1016/S0140-6736(20)30566-3. View

4.
Payen D, Faivre V, Miatello J, Leentjens J, Brumpt C, Tissieres P . Multicentric experience with interferon gamma therapy in sepsis induced immunosuppression. A case series. BMC Infect Dis. 2019; 19(1):931. PMC: 6833157. DOI: 10.1186/s12879-019-4526-x. View

5.
van Vught L, Klein Klouwenberg P, Spitoni C, Scicluna B, Wiewel M, Horn J . Incidence, Risk Factors, and Attributable Mortality of Secondary Infections in the Intensive Care Unit After Admission for Sepsis. JAMA. 2016; 315(14):1469-79. DOI: 10.1001/jama.2016.2691. View